Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection. by Bannard, O, Kraman, M, Fearon, D

Pathways of memory CD8+ T-cell development. by Bannard, O, Kraman, M, Fearon, D

Secondary replicative function of CD8+ T cells that had developed an effector phenotype. by Bannard, O, Kraman, M, Fearon, D

Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. by Mackay, L, Wakim, L, van Vliet, C, Jones, C, Mueller, SN, Bannard, O, Fearon, D, Heath, W, Carbone, F

Discovery and development strategies for SARS-CoV-2 NSP3 macrodomain inhibitors by Schuller, M, Zarganis-Tzitzikas, T, Bennett, J, De Cesco, S, Fearon, D, von Delft, F, Fedorov, O, Brennan, PE, Ahel, I

BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. by Manders, P, Hunter, P, Telaranta, A, Carr, J, Marshall, J, Carrasco, M, Murakami, Y, Palmowski, M, Cerundolo, V, Kaech, S, Ahmed, R, Fearon, D

Blockade of CTLA-4 promotes the development of effector CD8(+) T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. by Dos Santos, L, Galvão-Filho, B, de Faria, P, Junqueira, C, Dutra, MS, Teixeira, S, Rodrigues, M, Ritter, G, Bannard, O, Fearon, D, Antonelli, L, Gazzinelli, RT

Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase by Newman, JA, Douangamath, A, Yadzani, S, Yosaatmadja, Y, Aimon, A, Brandão-Neto, J, Dunnett, L, Gorrie-Stone, T, Skyner, R, Fearon, D, Schapira, M, von Delft, F, Gileadi, O

Exploring protein hotspots by optimized fragment pharmacophores by Bajusz, D, Wade, WS, Satała, G, Bojarski, AJ, Ilaš, J, Ebner, J, Grebien, F, Papp, H, Jakab, F, Douangamath, A, Fearon, D, von Delft, F, Schuller, M, Ahel, I, Wakefield, A, Vajda, S, Gerencsér, J, Pallai, P, Keserű, GM

Accelerating drug target inhibitor discovery with a deep generative foundation model by Chenthamarakshan, V, Hoffman, SC, Owen, CD, Lukacik, P, Strain-Damerell, C, Fearon, D, Malla, TR, Tumber, A, Schofield, CJ, Duyvesteyn, HME, Dejnirattisai, W, Carrique, L, Walter, TS, Screaton, GR, Matviiuk, T, Mojsilovic, A, Crain, J, Walsh, MA, Stuart, DI, Das, P

Expanding the repertoire of low-molecular-weight pentafluorosulfanyl-substituted scaffolds by Jose, A, Guest, D, LeGay, R, Tizzard, GJ, Coles, SJ, Derveni, M, Wright, E, Marrison, L, Lee, AA, Morris, A, Robinson, M, von Delft, F, Fearon, D, Koekemoer, L, Matviuk, T, Aimon, A, Schofield, CJ, Malla, TR, London, N, Greenland, BW, Bagley, MC, Spencer, J

Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19 by Redhead, MA, Owen, CD, Brewitz, L, Collette, AH, Lukacik, P, Strain-Damerell, C, Robinson, SW, Collins, PM, Schäfer, P, Swindells, M, Radoux, CJ, Hopkins, IN, Fearon, D, Douangamath, A, von Delft, F, Malla, TR, Vangeel, L, Vercruysse, T, Thibaut, J, Leyssen, P, Nguyen, T-T, Hull, M, Tumber, A, Hallett, DJ, Schofield, CJ, Stuart, DI, Hopkins, AL, Walsh, MA

Turning high-throughput structural biology into predictive inhibitor design by Saar, KL, McCorkindale, W, Fearon, D, Boby, M, Barr, H, Ben-Shmuel, A, London, N, von Delft, F, Chodera, JD, Lee, AA, Koekemoer, L, Krojer, T, Fairhead, M, MacLean, EM, Thompson, A, Smilova, MD, Wright, N, von Delft, A, Gileadi, C, Schofield, CJ, Salah, E, Malla, TR, Tumber, A, John, T, Vakonakis, I, Kantsadi, AL, Zitzmann, N, Brun, J, Kiappes, JL, Hill, M, Witt, KD, Alonzi, DS, Makower, LL, Giroud, C, Bennett, J, Fedorov, O, Morris, GM, Ferla, M, Carbery, A, Cattermole, E, Taylor, JC, Brewitz, L

Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking by Schuller, M, Correy, GJ, Gahbauer, S, Fearon, D, Wu, T, Díaz, RE, Young, ID, Carvalho Martins, L, Smith, DH, Schulze-Gahmen, U, Owens, TW, Deshpande, I, Merz, GE, Thwin, AC, Biel, JT, Peters, JK, Moritz, M, Herrera, N, Kratochvil, HT, Aimon, A, Bennett, JM, Brandao Neto, J, Cohen, AE, Dias, A, Douangamath, A, Dunnett, L, Fedorov, O, Ferla, MP, Fuchs, MR, Gorrie-Stone, TJ, Holton, JM, Johnson, MG, Krojer, T, Meigs, G, Powell, AJ, Rack, JGM, Rangel, VL, Russi, S, Skyner, RE, Smith, CA, Soares, AS, Wierman, JL, O'Brien, P, Zhu, K, Jura, N, Ashworth, A, Irwin, JJ, Thompson, MC, Gestwicki, JE, von Delft, F, Ahel, I

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors by Boby, ML, Fearon, D, Ferla, M, Filep, M, Koekemoer, L, Robinson, MC, Chodera, JD, Lee, AA, London, N, von Delft, A, von Delft, F, Achdout, H, Aimon, A, Alonzi, DS, Arbon, R, Aschenbrenner, JC, Balcomb, BH, Bar-David, E, Barr, H, Ben-Shmuel, A, Bennett, J, Bilenko, VA, Borden, B, Boulet, P, Bowman, GR, Brewitz, L, Brun, J, Bvnbs, S, Calmiano, M, Carbery, A, Carney, DW, Cattermole, E, Chang, E, Chernyshenko, E, Clyde, A, Coffland, JE, Cohen, G, Cole, JC, Contini, A, Cox, L, Croll, TI, Cvitkovic, M, De Jonghe, S, Dias, A, Donckers, K, Dotson, DL, Douangamath, A, Duberstein, S, Dudgeon, T, Fairhead, M, Taylor, JC, Zitzmann, N